Tumor-associated mitochondrial antigen (generic group, not a single molecule)

Tumor-associated mitochondrial antigens refer to mitochondrial proteins or mutated peptides derived from mitochondrial proteins that are presented on the surface of tumor cells as neoantigens—unique markers recognized by the immune system as non-self. These antigens can be derived from missense mutations in mitochondrial DNA or nuclear-encoded mitochondrial proteins, and their presentation by major histocompatibility complex (MHC) molecules makes them targets for recognition and elimination by CD8+ cytotoxic T cells. Experimental evidence suggests that mitochondrial localization enhances the immunogenicity of such antigens, and preclinical cancer vaccine studies using mitochondrial protein extracts have demonstrated induction of protective anti-tumor immune responses. However, the lack of a single, universally recognized molecule under the name "Tumor-associated mitochondrial antigen" means this term refers to a class or group of potential antigens, rather than a specific, defined therapeutic target[5][1][4]. The notion of targeting tumor-associated mitochondrial antigens is an emerging field; the scientific rationale lies in the fact that both nuclear and mitochondrial mutations in cancer can lead to unique mitochondrial neoantigens, potentially increasing tumor immunogenicity[5][1][4]. These antigens have been leveraged experimentally in cancer vaccines and are considered in the development of personalized immunotherapies, but have not yet led to any approved drugs or clearly defined receptor targets[5]. "Tumor-associated mitochondrial antigen" is not a unique, structurally-defined molecule or receptor, but rather a group of mitochondrial-derived antigens—proteins or peptides, often mutated in tumors—that can serve as targets for immune recognition in cancer therapy. Caution is warranted in using this term as a canonical target in structured data systems.

Other names

mitochondrial tumor antigenmitochondrial neoantigenmitochondrial protein-derived neoantigentumor mitochondrial antigen

Targeting of tumor cells by T cells specific for mitochondrial protein-derived antigens; Activation of cytotoxic CD8+ T cell responses via MHC class I presentation